{"id":15995,"date":"2026-05-08T13:55:13","date_gmt":"2026-05-08T06:55:13","guid":{"rendered":"https:\/\/vinphaco.net\/?p=15995"},"modified":"2026-05-08T13:55:13","modified_gmt":"2026-05-08T06:55:13","slug":"nebulizer-pharmaceutical-manufacturer","status":"publish","type":"post","link":"https:\/\/vinphaco.net\/pt-pt\/nebulizer-pharmaceutical-manufacturer\/","title":{"rendered":"Breakthrough Updates in COPD Treatment According to GOLD 2026 and the Importance of Nebulizer Therapy"},"content":{"rendered":"<p id=\"p-rc_823e643c579f5341-35\" data-path-to-node=\"7\"><span data-path-to-node=\"7,1\"><span class=\"citation-143\">Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous respiratory condition characterized by chronic symptoms (such as dyspnea, cough, and sputum production) and persistent airflow limitation<\/span><\/span><span data-path-to-node=\"7,3\">. <\/span><span data-path-to-node=\"7,5\"><span class=\"citation-142\">With the release of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2026 Report (the 6th major revision), multiple perspectives on epidemiology, classification, and treatment philosophy have been reshaped toward earlier intervention and more effective disease management<\/span><\/span><span data-path-to-node=\"7,7\">.<\/span><\/p>\n<p data-path-to-node=\"8\">As a dedicated <b data-path-to-node=\"8\" data-index-in-node=\"15\">nebulizer pharmaceutical manufacturer<\/b>, we aim to provide comprehensive clinical insights into these updates and the crucial role of inhalation therapies.<\/p>\n<p data-path-to-node=\"8\"><span data-path-to-node=\"15,3,1,0\"><b data-path-to-node=\"15,3,1,0\" data-index-in-node=\"0\"><span class=\"citation-125\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-15996\" src=\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download.png\" alt=\"Nebulizer pharmaceutical manufacturer\" width=\"224\" height=\"290\" \/><\/span><\/b><\/span><\/p>\n<h4 data-path-to-node=\"9\">1. The Updated Epidemiological Landscape of COPD in 2026<\/h4>\n<p id=\"p-rc_823e643c579f5341-36\" data-path-to-node=\"10\"><span data-path-to-node=\"10,1\"><span class=\"citation-141\">COPD continues to be a leading cause of morbidity and mortality globally, with an escalating economic and social burden<\/span><\/span><span data-path-to-node=\"10,3\">. <\/span><span data-path-to-node=\"10,5\"><span class=\"citation-140\">According to the latest epidemiological data from the GOLD 2026 report, the global number of COPD patients is projected to surge in the coming decades, approaching 600 million individuals by 2050<\/span><\/span><span data-path-to-node=\"10,7\">. <\/span><span data-path-to-node=\"10,9\"><span class=\"citation-139\">Notably, this increase will be more pronounced among females and in low- and middle-income countries (LMICs)<\/span><\/span><span data-path-to-node=\"10,11\">. <\/span><span data-path-to-node=\"10,13\"><span class=\"citation-138\">This rise results from continued exposure to risk factors (tobacco smoke, indoor\/outdoor air pollution from biomass fuel) combined with global population aging<\/span><\/span><span data-path-to-node=\"10,15\">.<\/span><\/p>\n<p id=\"p-rc_823e643c579f5341-37\" data-path-to-node=\"11\"><span data-path-to-node=\"11,1\"><span class=\"citation-137\">Accompanied by this increasing prevalence is a massive economic burden<\/span><\/span><span data-path-to-node=\"11,3\">. <\/span><span data-path-to-node=\"11,5\"><span class=\"citation-136\">GOLD 2026 data estimates that by 2050, global direct costs related to COPD will reach $24.35 trillion USD (a 526% increase from 2025), with indirect costs around $15.43 trillion USD, and exacerbation treatment costs alone accounting for $15.60 billion USD<\/span><\/span><span data-path-to-node=\"11,7\">.<\/span><\/p>\n<p id=\"p-rc_823e643c579f5341-38\" data-path-to-node=\"12\"><span data-path-to-node=\"12,1\"><span class=\"citation-135\">Although COPD is preventable and treatable, underdiagnosis, misdiagnosis, and late diagnosis remain major global challenges, preventing patients from accessing proper treatments<\/span><\/span><span data-path-to-node=\"12,3\">. Addressing these global treatment gaps requires the reliable supply chain of a dedicated nebulizer pharmaceutical manufacturer.<\/span><\/p>\n<h4 data-path-to-node=\"13\">2. Key Updates in COPD Management According to GOLD 2026<\/h4>\n<p id=\"p-rc_823e643c579f5341-39\" data-path-to-node=\"14\"><span data-path-to-node=\"14,1\"><span class=\"citation-134\">The GOLD 2026 report introduces systemic changes in the approach to COPD treatment<\/span><\/span><span data-path-to-node=\"14,3\">:<\/span><\/p>\n<ul>\n<li id=\"p-rc_823e643c579f5341-40\" data-path-to-node=\"15,0,1\"><span data-path-to-node=\"15,0,1,0\"><b data-path-to-node=\"15,0,1,0\" data-index-in-node=\"0\"><span class=\"citation-133\">Reclassification of Group E and Exacerbation Risk Assessment:<\/span><\/b><span class=\"citation-133\"> Evidence from recent observational studies indicates that even a single moderate or severe exacerbation before starting maintenance therapy significantly increases the risk of future events<\/span><\/span><span data-path-to-node=\"15,0,1,2\">. <\/span><span data-path-to-node=\"15,0,1,4\"><span class=\"citation-132\">Therefore, the threshold for Group E classification has been lowered: patients with at least one (\u2265 1) moderate or severe exacerbation in the past year are now classified into Group E<\/span><\/span><span data-path-to-node=\"15,0,1,6\">. <\/span><span data-path-to-node=\"15,0,1,8\"><span class=\"citation-131\">This aims to promote earlier treatment escalation<\/span><\/span><span data-path-to-node=\"15,0,1,10\">. <\/span><span data-path-to-node=\"15,0,1,12\"><span class=\"citation-130\">For Group E patients, the recommended initial regimen is dual bronchodilation (LABA + LAMA), considering Inhaled Corticosteroids (ICS) if blood eosinophils are \u2265 300 cells\/\u00b5L<\/span><\/span><span data-path-to-node=\"15,0,1,14\">.<\/span><\/li>\n<li id=\"p-rc_823e643c579f5341-41\" data-path-to-node=\"15,1,1\"><span data-path-to-node=\"15,1,1,0\"><b data-path-to-node=\"15,1,1,0\" data-index-in-node=\"0\"><span class=\"citation-129\">&#8220;Disease Stability&#8221; and &#8220;Disease Activity&#8221;:<\/span><\/b><span class=\"citation-129\"> For the first time, GOLD 2026 introduces these terms<\/span><\/span><span data-path-to-node=\"15,1,1,2\">. <\/span><span data-path-to-node=\"15,1,1,4\"><span class=\"citation-128\">Treatment must aim for &#8220;Disease Stability&#8221;\u2014returning the patient to a low disease activity state, characterized by the absence of exacerbations, no worsening of symptoms, and no rapid decline in lung function<\/span><\/span><span data-path-to-node=\"15,1,1,6\">. Achieving this stability heavily depends on quality medications produced by a top-tier nebulizer pharmaceutical manufacturer.<\/span><\/li>\n<li id=\"p-rc_823e643c579f5341-42\" data-path-to-node=\"15,2,1\"><span data-path-to-node=\"15,2,1,0\"><b data-path-to-node=\"15,2,1,0\" data-index-in-node=\"0\"><span class=\"citation-127\">Separation of Initial and Follow-up Treatment:<\/span><\/b><span class=\"citation-127\"> The report emphasizes the difference between INITIAL pharmacological treatment for newly diagnosed patients and FOLLOW-UP pharmacological treatment<\/span><\/span><span data-path-to-node=\"15,2,1,2\">. <\/span><span data-path-to-node=\"15,2,1,4\"><span class=\"citation-126\">In the follow-up phase, optimizing the regimen focuses on two main treatable traits: persistent dyspnea and exacerbation frequency<\/span><\/span><span data-path-to-node=\"15,2,1,6\">.<\/span><\/li>\n<li id=\"p-rc_823e643c579f5341-43\" data-path-to-node=\"15,3,1\"><span data-path-to-node=\"15,3,1,0\"><b data-path-to-node=\"15,3,1,0\" data-index-in-node=\"0\"><span class=\"citation-125\">Vaccines and Artificial Intelligence (AI):<\/span><\/b><span class=\"citation-125\"> Guidelines for RSV and influenza vaccines have been updated<\/span><\/span><span data-path-to-node=\"15,3,1,2\">. <\/span><span data-path-to-node=\"15,3,1,4\"><span class=\"citation-124\">Furthermore, GOLD 2026 adds Chapter 6 on AI and remote monitoring to improve early diagnosis and manage complex multimorbidities in COPD patients<\/span><\/span><span data-path-to-node=\"15,3,1,6\">.<\/span><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-16012 aligncenter\" src=\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download-2-640x539.png\" alt=\"\" width=\"640\" height=\"539\" srcset=\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download-2-640x539.png 640w, https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download-2-768x647.png 768w, https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download-2-320x270.png 320w, https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download-2-800x674.png 800w, https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/05\/download-2.png 845w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/li>\n<\/ul>\n<h4 data-path-to-node=\"16\">3. The Vital Role of Inhaled Bronchodilators in the New Paradigm<\/h4>\n<p id=\"p-rc_823e643c579f5341-44\" data-path-to-node=\"17\"><span data-path-to-node=\"17,1\"><span class=\"citation-123\">To achieve the strict &#8220;Disease Stability&#8221; goal, proper drug delivery is decisive<\/span><\/span><span data-path-to-node=\"17,3\">. <\/span><span data-path-to-node=\"17,5\"><span class=\"citation-122\">Most COPD medications (SABA, SAMA, LABA, LAMA, ICS) are administered via inhalation<\/span><\/span><span data-path-to-node=\"17,7\">.<\/span><\/p>\n<h4 data-path-to-node=\"18\">Device Customization and Efficacy<\/h4>\n<p id=\"p-rc_823e643c579f5341-45\" data-path-to-node=\"19\"><span data-path-to-node=\"19,1\"><span class=\"citation-121\">According to GOLD 2026, randomized controlled trials do not show the superiority of one device type over another (including nebulizers vs. handheld devices like pMDI, DPI, SMI), provided the patient uses the device correctly<\/span><\/span><span data-path-to-node=\"19,3\">. <\/span><span data-path-to-node=\"19,5\"><span class=\"citation-120\">However, for older or frail COPD patients with suboptimal peak inspiratory flow, using a nebulizer is an excellent alternative<\/span><\/span><span data-path-to-node=\"19,7\">. <\/span><span data-path-to-node=\"19,9\"><span class=\"citation-119\">It ensures medication reaches the bronchioles without requiring strong inhalation force<\/span><\/span><span data-path-to-node=\"19,11\">. <\/span><span data-path-to-node=\"19,13\"><span class=\"citation-118\">As a specialized <\/span><b data-path-to-node=\"19,13\" data-index-in-node=\"17\"><span class=\"citation-118\">nebulizer pharmaceutical manufacturer<\/span><\/b><span class=\"citation-118\">, we recognize that preventing inhaler technique errors is vital for cost control and disease management<\/span><\/span><span data-path-to-node=\"19,15\">.<\/span><\/p>\n<h4 data-path-to-node=\"20\">Exacerbation Management<\/h4>\n<p id=\"p-rc_823e643c579f5341-46\" data-path-to-node=\"21\"><span data-path-to-node=\"21,1\"><span class=\"citation-117\">With the new criteria, managing exacerbations is critical<\/span><\/span><span data-path-to-node=\"21,3\">. <\/span><span data-path-to-node=\"21,5\"><span class=\"citation-116\">Short-acting bronchodilators are recommended as initial therapy for acute exacerbations<\/span><\/span><span data-path-to-node=\"21,7\">. <\/span><span data-path-to-node=\"21,9\"><span class=\"citation-115\">Increasing the bronchodilator dose significantly above the maintenance dose, especially via a nebulizer, has been proven to provide marked subjective improvement during exacerbations<\/span><\/span><span data-path-to-node=\"21,11\">. <\/span><span data-path-to-node=\"21,13\"><span class=\"citation-114\">Nebulizers deliver a larger drug volume, rapidly dilating bronchial smooth muscle and reducing dynamic hyperinflation, thereby immediately decreasing the work of breathing and dyspnea<\/span><\/span><span data-path-to-node=\"21,15\">. This is exactly why hospitals rely on a trusted nebulizer pharmaceutical manufacturer for fast-acting liquid respiratory medications.<\/span><\/p>\n<h4 data-path-to-node=\"22\">Compliance and Symptom Control<\/h4>\n<p id=\"p-rc_823e643c579f5341-47\" data-path-to-node=\"23\"><span data-path-to-node=\"23,1\"><span class=\"citation-113\">If dyspnea persists despite long-acting bronchodilators, GOLD 2026 advises switching inhaler devices or combining medications<\/span><\/span><span data-path-to-node=\"23,3\">. <\/span><span data-path-to-node=\"23,5\"><span class=\"citation-112\">Modern nebulizer systems, combined with self-management education, can enhance compliance and resolve persistent dyspnea, improving the patient&#8217;s quality of life<\/span><\/span><span data-path-to-node=\"23,7\">.<\/span><\/p>\n<h2 data-path-to-node=\"24\">Conclusion<\/h2>\n<p id=\"p-rc_823e643c579f5341-48\" data-path-to-node=\"25\"><span data-path-to-node=\"25,1\"><span class=\"citation-111\">The GOLD 2026 report marks a shift from passive treatment to proactive intervention<\/span><\/span><span data-path-to-node=\"25,3\">. <\/span><span data-path-to-node=\"25,5\"><span class=\"citation-110\">Facing the burden of 600 million projected cases by 2050, fully utilizing bronchodilators via inhalation systems (inhalers, nebulizers) and ensuring technique compliance is the key<\/span><\/span><span data-path-to-node=\"25,7\">.<\/span><\/p>\n<p data-path-to-node=\"25\">\n<p data-path-to-node=\"26\">*** <i data-path-to-node=\"26\" data-index-in-node=\"4\">As a reliable <b data-path-to-node=\"26\" data-index-in-node=\"18\">nebulizer pharmaceutical manufacturer<\/b> operating under strict GMP-WHO standards, we are committed to providing high-quality respiratory solutions. Partnering with a proven <b data-path-to-node=\"26\" data-index-in-node=\"189\">nebulizer pharmaceutical manufacturer<\/b> ensures a robust supply chain for essential COPD therapies. [<a href=\"https:\/\/vinphaco.net\/\">Contact our Export Department]<\/a> today to explore our contract manufacturing capabilities. For full clinical guidelines, review the <a href=\"https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/\" target=\"_blank\" rel=\"noopener\">[GOLD 2026 Report].<\/a><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous respiratory condition characterized by chronic symptoms (such as dyspnea, cough, and sputum production) and persistent airflow limitation. With the release of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2026 Report (the 6th major revision), multiple perspectives on epidemiology, classification, and treatment philosophy&#8230;<\/p>\n","protected":false},"author":5,"featured_media":15996,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[294],"tags":[1197,1198,1200,1199,1196,1183],"class_list":["post-15995","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations-medicales","tag-copd-treatment-2026","tag-gold-2026-report","tag-inhalation-therapy","tag-nebulizer-medication","tag-nebulizer-pharmaceutical-manufacturer","tag-vietnam-pharmaceutical-manufacturer"],"acf":[],"_links":{"self":[{"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/posts\/15995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/comments?post=15995"}],"version-history":[{"count":1,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/posts\/15995\/revisions"}],"predecessor-version":[{"id":16020,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/posts\/15995\/revisions\/16020"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/media\/15996"}],"wp:attachment":[{"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/media?parent=15995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/categories?post=15995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vinphaco.net\/pt-pt\/wp-json\/wp\/v2\/tags?post=15995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}